A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ONCE-DAILY ADMINISTRATION OF A PHOSPHODIESTERASE 5 INHIBITOR (PF-00489791) IN ADULTS WITH TYPE 2 DIABETES AND OVERT NEPHROPATHY
Latest Information Update: 03 Oct 2021
At a glance
- Drugs PF 489791 (Primary)
- Indications Diabetic nephropathies
- Focus Therapeutic Use
- Sponsors Pfizer
- 19 May 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 15 May 2013 Planned end date changed from 1 Apr 2013 to 1 Aug 2013 as reported by ClinicalTrials.gov.
- 15 May 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.